{"id":30534,"date":"2024-12-06T17:35:00","date_gmt":"2024-12-06T12:05:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30534"},"modified":"2025-09-15T10:37:27","modified_gmt":"2025-09-15T05:07:27","slug":"celiac-disease-therapies-to-watch-out","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out","title":{"rendered":"Top 6 Celiac Disease Therapies Progressing in Mid-Stage Trials"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3b729e9eeaa\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3b729e9eeaa\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#6_Celiac_Disease_Therapies_in_Mid-Stage_Development\" >6 Celiac Disease Therapies in Mid-Stage Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#Sanofis_PRV-015\" >Sanofi\u2019s PRV-015<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#Takedas_TAK-101_TAK-227_Zamaglutenase\" >Takeda\u2019s TAK-101; TAK-227; Zamaglutenase<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#Entero_Therapeutics_Latiglutenase\" >Entero Therapeutics\u2019 Latiglutenase<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#Kanyos_BioAnokions_KAN_101\" >Kanyos Bio\/Anokion\u2019s KAN 101<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\/#Future_Outlook_of_Celiac_Disease_Treatment\" >Future Outlook of Celiac Disease Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>At present, there are no FDA-approved celiac disease therapies in the therapeutic segment. The only available treatment is a strict, lifelong gluten-free diet, which can be costly and challenging to follow. Many patients experience incomplete intestinal healing and persistent symptoms, often due to difficulties in maintaining full adherence to the diet. Promising celiac disease drug therapies are under development to ease the burden of managing celiac disease and enhance long-term health outcomes.<\/p>\n\n\n\n<p><strong><em>Read our latest article \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-treatment\"><strong><em>Who Will Secure First-Mover Advantage in the Celiac Disease Treatment Space?<\/em><\/strong><\/a><strong><em>\u201d and get a complete overview<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-6-celiac-disease-therapies-in-mid-stage-development\"><span class=\"ez-toc-section\" id=\"6_Celiac_Disease_Therapies_in_Mid-Stage_Development\"><\/span><strong>6 Celiac Disease Therapies in Mid-Stage Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/celiac-disease-pipeline-insight\">Celiac Disease Pipeline Report<\/a>, over <strong>25 companies<\/strong> are actively working in the celiac disease treatment field worldwide. Notable drugs in development include <strong>Latiglutenase<\/strong> (First Wave BioPharma), <strong>TAK-101, TAK-227, and Zamaglutenase<\/strong> (Takeda), as well as <strong>PRV-015<\/strong> (Provention Bio\/Sanofi), and <strong>KAN-101<\/strong> (Kanyos Bio\/Anokion), among others. Let\u2019s take a closer look at these emerging celiac disease therapies in detail.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sanofi-s-prv-015\"><span class=\"ez-toc-section\" id=\"Sanofis_PRV-015\"><\/span><strong>Sanofi\u2019s PRV-015<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>PRV-015 (Ordesekimab, AMG 714)<\/strong> is a fully human IgG1\u03ba monoclonal antibody being developed by Provention Bio for the treatment of Celiac Disease that does not respond to a gluten-free diet. Originally developed by Amgen for rheumatoid arthritis, the drug is currently undergoing a <strong>Phase II clinical trial (PROACTIVE)<\/strong> in adult patients with non-responsive celiac disease (NRCD) who are following a gluten-free diet. In March 2023, Sanofi acquired <strong>Provention Bio<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-takeda-s-tak-101-tak-227-zamaglutenase\"><span class=\"ez-toc-section\" id=\"Takedas_TAK-101_TAK-227_Zamaglutenase\"><\/span><strong>Takeda\u2019s TAK-101; TAK-227; Zamaglutenase<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Takeda is progressing with a portfolio of investigational therapies for potential celiac disease treatments. <strong>TAK-101 (CNP-101\/TIMP-GLIA)<\/strong> is a first-in-class, immune-modulating biodegradable nanoparticle containing gliadin proteins, currently being developed by Takeda for celiac disease. The drug has received <strong>Fast Track designation<\/strong> from the US FDA for this condition. Another drug, <strong>Zamaglutenase (TAK-062),<\/strong> is in Phase II clinical trials to prevent gluten-specific T cell activation in patients with celiac disease following a gluten-free diet (GFD).&nbsp;<\/p>\n\n\n\n<p>Additionally, <strong>TAK-227 (ZED1227)<\/strong>, another <a href=\"https:\/\/www.delveinsight.com\/report-store\/celiac-disease-cd-market\">celiac disease drug<\/a> in Takeda\u2019s pipeline, is in Phase IIb for celiac disease treatment. In October 2022, Takeda agreed with <strong>Zedira and Dr. Falk Pharma<\/strong> to further develop ZED1227\/TAK-227. Zedira originally discovered the drug, and Dr. Falk Pharma obtained European rights in 2011, taking on responsibility for its preclinical and clinical development. Takeda expects to release Phase II results for TAK-227 by 2024.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"519\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-1024x519.png\" alt=\"Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development\" class=\"wp-image-30505\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-1024x519.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-300x152.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-150x76.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-768x389.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-1536x779.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02155818\/Emerging-Celiac-Disease-Therapies-in-Mid-Stage-of-Development-2048x1039.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-entero-therapeutics-latiglutenase\"><span class=\"ez-toc-section\" id=\"Entero_Therapeutics_Latiglutenase\"><\/span><strong>Entero Therapeutics\u2019 Latiglutenase<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Latiglutenase (IMGX003)<\/strong> is an oral treatment consisting of two gluten-specific recombinant proteases that break down gluten proteins into small, physiologically insignificant fragments. It is intended as an adjunct to a gluten-free diet (GFD). In Phase IIa and IIb clinical trials, latiglutenase demonstrated its ability to reduce gluten-induced intestinal mucosal damage and alleviate the severity and frequency of symptoms in patients with celiac disease.&nbsp;<\/p>\n\n\n\n<p>The Phase III clinical development plan for latiglutenase has been reviewed by the GI Division of the US FDA, and the trials are expected to begin in early <strong>2025<\/strong>. Additionally, a strategic US commercial licensing agreement with a global pharmaceutical company, along with concurrent institutional investment, is anticipated to be finalized in the second half of <strong>2024<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-kanyos-bio-anokion-s-kan-101\"><span class=\"ez-toc-section\" id=\"Kanyos_BioAnokions_KAN_101\"><\/span><strong>Kanyos Bio\/Anokion\u2019s KAN 101<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>KAN-101<\/strong> is an experimental therapy being tested as a potential treatment for celiac disease, a severe autoimmune disorder triggered by gluten consumption, for which no approved treatments currently exist. The therapy aims to promote tolerance to gliadin, a key component of gluten, by leveraging natural mechanisms in the liver. The FDA has granted KAN-101 <strong>Fast Track designation<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/celiac-disease-cd-market\">treatment of celiac disease<\/a>.<\/p>\n\n\n\n<p>In September 2023, Anokion announced clinical progress with KAN-101. The company has begun patient dosing in the global Phase II segment of the <strong>ACeD-it (Assessment of KAN-101 in Celiac Disease and Immune Tolerance) clinical trial,<\/strong> focusing on individuals with celiac disease. The ACeD-it study is composed of two phases: Phase Ib is an open-label, multiple ascending dose study to evaluate the safety and tolerability of higher doses of KAN-101 in celiac patients compared to the Phase I trial; Phase II is a double-blind, placebo-controlled trial aimed at assessing KAN-101\u2019s impact on the gluten-induced IL-2 biomarker and celiac symptoms. KAN-101 is an innovative immune tolerance therapy using a gluten antigen delivered to the liver and immune system via the company&#8217;s proprietary liver-targeting technology.<\/p>\n\n\n\n<p>The primary goal of the ACeD-it Phase II is to evaluate the effect on gluten-induced IL-2 biomarker responses. Key secondary objectives include measuring adverse events and pharmacokinetic parameters in patients treated with KAN-101, along with assessing symptom improvements in celiac disease following gluten exposure. The study will be conducted at sites in the US, Australia, and New Zealand. Anokion expects to report topline results in <strong>2024<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-outlook-of-celiac-disease-treatment\"><span class=\"ez-toc-section\" id=\"Future_Outlook_of_Celiac_Disease_Treatment\"><\/span><strong>Future Outlook of Celiac Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future outlook for celiac disease treatment is promising, with ongoing research focusing on both therapeutic interventions and diagnostic advancements. Currently, the only treatment available is a strict gluten-free diet, but this does not fully address the disease\u2019s underlying mechanisms. However, promising therapies are in development, including enzyme-based treatments that can help break down gluten in the digestive system, reducing the immune response. Oral immunotherapy is also being explored to desensitize the immune system to gluten exposure, potentially offering a long-term solution for patients who struggle with strict dietary management. Additionally, biologic drugs that target specific immune pathways responsible for celiac disease are being investigated, opening new avenues for treatment.<\/p>\n\n\n\n<p>Another area of significant research involves enhancing diagnostic tools and expanding screening options for early detection of celiac disease. Improved biomarkers, blood tests, and genetic screening may lead to earlier intervention, preventing severe complications associated with untreated celiac disease, such as nutrient deficiencies, infertility, or autoimmune conditions. The development of a vaccine or therapy to allow for the safe consumption of gluten without triggering an immune response remains a long-term goal.&nbsp;<\/p>\n\n\n\n<p>Additionally, several companies are evaluating their lead assets in various clinical trials. The introduction of these new therapies for celiac disease is set to have a major impact on the market by providing alternative treatment options for patients who have traditionally relied on a strict gluten-free diet. These groundbreaking therapies target the immune response and aim to improve symptom management, enhancing patients&#8217; quality of life and encouraging better adherence to treatment.&nbsp;<\/p>\n\n\n\n<p>With improved symptom control and the possibility of modifying the disease, these <a href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-treatment\">celiac disease therapies<\/a> could help prevent long-term complications like osteoporosis, infertility, and an elevated risk of certain cancers. As these treatments become available, they are expected to spark increased interest from healthcare professionals and patients alike, potentially broadening the market for celiac disease treatments and changing the approach to managing the condition.<\/p>\n\n\n\n<p>As science advances, these innovations, combined with personalized medicine, could significantly improve the quality of life for individuals with celiac disease and potentially offer a cure or more effective management options in the future.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/celiac-disease-cd-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-1024x194.png\" alt=\"Celiac-Disease-Market-Outlook\" class=\"wp-image-30500\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/02154924\/Celiac-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>FAQs<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757912696814\"><strong class=\"schema-faq-question\"><strong>Why is a strict gluten-free diet not enough for many celiac patients?<\/strong><\/strong> <p class=\"schema-faq-answer\">Although a gluten-free diet is currently the only available treatment, many patients struggle with adherence, leading to incomplete intestinal healing and persistent symptoms. This creates a significant unmet need for alternative therapies.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757912697619\"><strong class=\"schema-faq-question\"><strong>Which companies are leading the development of celiac disease therapies?<\/strong><\/strong> <p class=\"schema-faq-answer\">Over 25 companies are actively working in this space, including Takeda (TAK-101, TAK-227, Zamaglutenase), Sanofi\/Provention Bio (PRV-015), Entero Therapeutics (Latiglutenase), and Kanyos Bio\/Anokion (KAN-101). Each is exploring unique mechanisms to improve patient outcomes.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757912698125\"><strong class=\"schema-faq-question\"><strong>What makes PRV-015 a promising candidate?<\/strong><\/strong> <p class=\"schema-faq-answer\">PRV-015 (Ordesekimab) is a fully human monoclonal antibody targeting non-responsive celiac disease. Originally developed for rheumatoid arthritis, it is now in Phase II trials for patients who continue to experience symptoms despite following a gluten-free diet.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757912698612\"><strong class=\"schema-faq-question\"><strong>How does Takeda\u2019s pipeline aim to tackle celiac disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Takeda is advancing multiple mid-stage therapies, including TAK-101, an immune-modulating nanoparticle, TAK-227, a selective transglutaminase 2 inhibitor, and Zamaglutenase, which prevents gluten-specific T cell activation, targeting key disease mechanisms beyond dietary management.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757912700302\"><strong class=\"schema-faq-question\"><strong>What is unique about KAN-101\u2019s approach?<\/strong><\/strong> <p class=\"schema-faq-answer\">KAN-101 promotes immune tolerance to gliadin using liver-targeted antigen delivery. Its Phase II trial focuses on reducing gluten-induced IL-2 responses and improving celiac symptoms, representing a novel immune-modulatory strategy for long-term disease control.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757912806929\"><strong class=\"schema-faq-question\"><strong>What does the future hold for celiac disease treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">Emerging therapies, including enzyme-based treatments, oral immunotherapies, and biologics, aim to reduce immune responses, improve symptom control, and prevent long-term complications. Combined with better diagnostics and personalized approaches, these innovations could redefine disease management.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>At present, there are no FDA-approved celiac disease therapies in the therapeutic segment. The only available treatment is a strict, lifelong gluten-free diet, which can be costly and challenging to follow. Many patients experience incomplete intestinal healing and persistent symptoms, often due to difficulties in maintaining full adherence to the diet. Promising celiac disease drug [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30536,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1178,18663,17602,1179,18661,18662],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-30534","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-celiac-disease","tag-celiac-disease-drugs","tag-celiac-disease-market","tag-celiac-disease-market-share","tag-celiac-disease-market-size","tag-celiac-disease-pipeline","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>6 Celiac Disease Therapies to Watch Out<\/title>\n<meta name=\"description\" content=\"Over 25 companies are working in celiac disease treatment field globally. Notable drugs include Latiglutenase, TAK-101, TAK-227, among others.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"6 Celiac Disease Therapies to Watch Out\" \/>\n<meta property=\"og:description\" content=\"Over 25 companies are working in celiac disease treatment field globally. Notable drugs include Latiglutenase, TAK-101, TAK-227, among others.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T12:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T05:07:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"6 Celiac Disease Therapies to Watch Out","description":"Over 25 companies are working in celiac disease treatment field globally. Notable drugs include Latiglutenase, TAK-101, TAK-227, among others.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out","og_locale":"en_US","og_type":"article","og_title":"6 Celiac Disease Therapies to Watch Out","og_description":"Over 25 companies are working in celiac disease treatment field globally. Notable drugs include Latiglutenase, TAK-101, TAK-227, among others.","og_url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-06T12:05:00+00:00","article_modified_time":"2025-09-15T05:07:27+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out","url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out","name":"6 Celiac Disease Therapies to Watch Out","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out.jpg","datePublished":"2024-12-06T12:05:00+00:00","dateModified":"2025-09-15T05:07:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Over 25 companies are working in celiac disease treatment field globally. Notable drugs include Latiglutenase, TAK-101, TAK-227, among others.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912696814"},{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912697619"},{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698125"},{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698612"},{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912700302"},{"@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912806929"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out.jpg","width":466,"height":284,"caption":"celiac-disease-therapies-to-watch-out"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912696814","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912696814","name":"Why is a strict gluten-free diet not enough for many celiac patients?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Although a gluten-free diet is currently the only available treatment, many patients struggle with adherence, leading to incomplete intestinal healing and persistent symptoms. This creates a significant unmet need for alternative therapies.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912697619","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912697619","name":"Which companies are leading the development of celiac disease therapies?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Over 25 companies are actively working in this space, including Takeda (TAK-101, TAK-227, Zamaglutenase), Sanofi\/Provention Bio (PRV-015), Entero Therapeutics (Latiglutenase), and Kanyos Bio\/Anokion (KAN-101). Each is exploring unique mechanisms to improve patient outcomes.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698125","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698125","name":"What makes PRV-015 a promising candidate?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"PRV-015 (Ordesekimab) is a fully human monoclonal antibody targeting non-responsive celiac disease. Originally developed for rheumatoid arthritis, it is now in Phase II trials for patients who continue to experience symptoms despite following a gluten-free diet.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698612","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912698612","name":"How does Takeda\u2019s pipeline aim to tackle celiac disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Takeda is advancing multiple mid-stage therapies, including TAK-101, an immune-modulating nanoparticle, TAK-227, a selective transglutaminase 2 inhibitor, and Zamaglutenase, which prevents gluten-specific T cell activation, targeting key disease mechanisms beyond dietary management.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912700302","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912700302","name":"What is unique about KAN-101\u2019s approach?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"KAN-101 promotes immune tolerance to gliadin using liver-targeted antigen delivery. Its Phase II trial focuses on reducing gluten-induced IL-2 responses and improving celiac symptoms, representing a novel immune-modulatory strategy for long-term disease control.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912806929","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/celiac-disease-therapies-to-watch-out#faq-question-1757912806929","name":"What does the future hold for celiac disease treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Emerging therapies, including enzyme-based treatments, oral immunotherapies, and biologics, aim to reduce immune responses, improve symptom control, and prevent long-term complications. Combined with better diagnostics and personalized approaches, these innovations could redefine disease management.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/06120157\/celiac-disease-therapies-to-watch-out-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease market share<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease Market Size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celiac Disease Pipeline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Celiac Disease<\/span>","<span class=\"advgb-post-tax-term\">Celiac Disease Drugs<\/span>","<span class=\"advgb-post-tax-term\">Celiac Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Celiac Disease market share<\/span>","<span class=\"advgb-post-tax-term\">Celiac Disease Market Size<\/span>","<span class=\"advgb-post-tax-term\">Celiac Disease Pipeline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 9 months ago"},"absolute_dates":{"created":"Posted on Dec 6, 2024","modified":"Updated on Sep 15, 2025"},"absolute_dates_time":{"created":"Posted on Dec 6, 2024 5:35 pm","modified":"Updated on Sep 15, 2025 10:37 am"},"featured_img_caption":"celiac-disease-therapies-to-watch-out","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30534"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30534\/revisions"}],"predecessor-version":[{"id":33395,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30534\/revisions\/33395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30536"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30534"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30534"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}